Lowering lipids with or without statins

January 2009
British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p9
Academic Journal
The article offers information on the study conducted regarding the efficacy of Tredaptive 2 grams, nicotinic acid/laropiprant, in treating dyslipidaemia and primary hypercholesterolaemia in Great Britain. Results of the Phase III research reveal that the drug offers a vital 18% reduction from baseline in low-density lipoprotein cholesterol, a 20% increase in high density lipoprotein cholesterol and a 26% reduction in triglycerides compared to placebo.


Related Articles

  • HDL cholesterol and cardiovascular risk. Ghali, William A.; Rodondi, Nicolas // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/28/2009, p488 

    The authors reflect on HDL cholesterol and cardiovascular risk. They suggest that treatments that increase HDL cholesterol do not reduce the risk of cardiovascular problems. They argue that research suggests that LDL cholesterol should be the primary target of lipid lowering; treatments and that...

  • Oxymetholone.  // Reactions Weekly;11/10/2007, Issue 1177, p22 

    The article describes the case of a 39-year-old male patient who developed decreased levels of High Density Lipoprotein (HDL) cholesterol during treatment with oxymetholone. The patient was diagnosed with hypercholesterolaemia and a decrease in HDL-cholesterol levels. The patient also had a...

  • Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. van Aalst-Cohen, Emily S.; Jansen, Angelique C. M.; Boekholdt, S. Matthijs; Tanck, Michael W. T.; Fontecha, Marcel R.; Cheng, Suzanne; Jia Li; Defesche, Joep C.; Kuivenhoven, Jan Albert; Kastelein, John J. P. // European Journal of Human Genetics;Oct2005, Vol. 13 Issue 10, p1137 

    The objective of this study was to determine the extent to which common genetic variants can explain the variation of high-density lipoprotein cholesterol (HDL-C) plasma levels in familial hypercholesterolemia (FH). FH is characterized by elevated low-density lipoprotein cholesterol levels and...

  • Comparisons of Referral Criteria for Public Screening of Blood Cholesterol Levels. Wones, Robert G.; Kerman, Keith M.; Hissa, Deborah C.; Meloy, Nannette; Stein, Evan A. // Public Health Reports;Sep/Oct89, Vol. 104 Issue 5, p425 

    Total and high-density lipoprotein (HDL) cholesterol levels of 2,387 adults were screened at a worksite and a bloodbank. Hypothetical referral decisions were made according to three sets of guidelines: the 1984 National Institutes of Health Consensus Conference guidelines (NIHCC), a single...

  • Gene points to HDL drug target. Moberly, Tom // GP: General Practitioner;3/20/2009, p6 

    The article reports on the study concerning development of a new cholesterol drug after the discovery of a gene mutation that raises high-density lipoprotein (HDL) levels. Result of the study shows that a drug which blocked the endothelial lipase function would lead to the increase of HDL...

  • Effects of Intravenous Apo A-I, HDLs and Apo A-I/Phospholipid Discs on Vascular Metabolism and Atherosclerosis in Animals and Humans. Miller, Norman E.; Nanjee, M. Nazeem; Miller, Irina. P.; Brinton, Eliot A. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Aug2005, Vol. 5 Issue 4, p315 

    High-density lipoproteins (HDLs) have several metabolic actions in vitro that are potentially anti-atherogenic. In addition to their role in reverse cholesterol transport, native HDLs have been shown to protect low-density lipoproteins (LDLs) against oxidative modification, to have...

  • When good cholesterol goes bad. Fogelman, Alan M. // Nature Medicine;Sep2004, Vol. 10 Issue 9, p902 

    Reports on research concerning the high density lipoprotein (HDL) cholesterol. Occurrence of heart attacks and strokes in persons with perfectly normal cholesterol levels; Role of HDL in patients with cardiovascular disease; Examination of proinflammatory or dysfunctional HDL.

  • Non-HDL-C and total cholesterol/HDL-C best predictors of heart health.  // Contemporary OB/GYN;Sep2005, Vol. 50 Issue 9, p16 

    Discusses research being done on the efficacy of non-high-density lipoprotein cholesterol (non-HDL-C) and the ratio of total cholesterol to HDL-C as predictors of future cardiovascular events. Reference to a study by P. M. Ridker and colleagues published in a 2005 issue of the "Journal of the...

  • Drugs that change cholesterol levels.  // Consumer Reports on Health;Sep2004, Vol. 16 Issue 9, p7 

    Lists several drugs that change low density lipoprotein and high density lipoprotein cholesterol level in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics